Biosimilar Patent Infringement Cases in 2025 Amid a Looming Patent Cliff
Introduction: A Wave of Biosimilar Challenges and the "Patent Cliff"
The biopharmaceutical industry is witnessing a surge of
Bristol Myers Squibb's $300 Million Autoimmune Spinout – Investors, Precedents, and Financing Structure
Investor Syndicate and Stakeholders in the $300 Million Round
The new biotech (not yet officially named) is backed by a
Fund of the week: DRI Healthcare
Origin Story: From Niche Pioneer to Public Trust
DRI Healthcare's roots go back to 1989, when it began
Private equity biotech investment landscape in Q3 2025
The biotech investment ecosystem in late August 2025 presents a complex landscape of cautious recovery, selective capital deployment, and strategic
The psychedelics sector faces a brutal financial reckoning as cash burn rates collide with regulatory setbacks
The psychedelics industry entered August 2025 with approximately $1.2 billion in combined cash reserves across six major public companies,
The AI Infrastructure Shift: When Cloud Evangelists Build Their Own Computers
The great wheel of computing infrastructure turns full circle: from centralized mainframes to distributed systems to cloud centralization and now
The weekly term sheet (34)
Biopharma dealmaking slows amid regulatory storm
The week of August 18-23, 2025 marked an unusually subdued period for biopharma transactions,
Company of the week: Palantir
The pharmaceutical industry's adoption of Palantir Technologies reveals a fundamental tension in enterprise software architecture that goes beyond
Fund of the week: ARCH Venture Partners
ARCH Venture Partners has raised over $3 billion for its thirteenth fund, cementing its position as one of biotech'
Collateralized Fund Obligations: The $7 Trillion Question for Biotech Financing
The recent closure of AlpInvest's $1 billion collateralized fund obligation marks a potential inflection point for biotech financing.
